The Future of Decisioning
August 20, 2026 | Havas Lynx, Point.1
The traditional model for gathering insights is reaching a breaking point. Healthcare Professionals (HCPs) are increasingly time-poor and difficult to reach. Simultaneously, the costs of traditional market research are rising, while the compressed timelines of global launch cycles demand faster results than ever. We are caught in a paradox: the pressure to accelerate our decision-making is clashing with the absolute necessity for deep, actionable customer understanding.
This is why synthetic testing is not just a trend, it’s a strategic imperative.
The Power of SensAI
Point.1’s SensAI is built for Pharma, by Pharma. Our synthetic personas are not generic; they’re constructed from the industry’s most robust comms-based HCP dataset: 11,000+ professionals across 8+ geographies and 10+ therapy areas, with 2,500+ variables per respondent.
And we go further. SensAI integrates Lexicon analysis to identify critical knowledge gaps, hundreds of award-winning case studies to establish “best-in-class” benchmarks, and competitor norms to ensure true brand differentiation. By aligning this data with behavioural science, we create a 360-degree view that transforms raw data into strategic creative scoring.
Putting It to the Test
The common scepticism surrounding synthetic testing is: Can it really replace human insight? We put that question to the test by running a head-to-head comparison with traditional human quantitative research.
The results were statistically compelling. Our synthetic testing achieved an 86% predictive match with human benchmarks, with correlation of R=0.93 for PCPs and R=0.84 for Neurologists.
The figures prove that our AI doesn’t just mimic human responses; it mirrors them with high statistical confidence, allowing teams to down-select concepts with rigorous evidence.
A New Framework for the Future
To be clear: synthetic testing is a guide, not a replacement for human judgment. AI is an algorithm, and its value is defined by its foundational architecture. However, when deployed within a testing framework, it allows teams to iterate at speed, killing “dead-on-arrival” concepts before they consume precious human research budgets. It’s about making smarter decisions: 40% faster and significantly cheaper.
Why choose SensAI? Because our dataset is built with Pharma marcomms objectives at its heart. We don’t just understand the HCP’s professional background; we understand their personal drivers, their content preferences, and the specific touchpoints where they engage.
As we move toward a future of faster launches and tighter budgets, the brands that win will be those that use synthetic personas to de-risk their strategy early. The future of decisioning is here, and it is built on robust, data-driven confidence.
This content was provided by Havas Lynx
Company Details
Latest Content from Havas Lynx
The Future of Decisioning
The traditional model for gathering insights is reaching a breaking point. Healthcare Professionals (HCPs) are increasingly time-poor and difficult to reach. Simultaneously, the costs of traditional market research are rising,…
Havas Lynx celebrates 40 years of impact
Starting out in 1986 as a team of two in Manchester’s Northern Quarter, Havas Lynx has much to celebrate, having grown to become an international healthcare communications agency with offices…
Doctored Truths
When the truth is doctored, lives hang in the balance.
Climate of Health
What’s happening to our planet is having an undeniable and devastating impact across every aspect of human health. What harms the world, harms us all. And these effects are so…
Passion and Pain: Millennial HCP Report
When we investigate millennial healthcare professionals (HCPs), we see a generation experiencing a clash of two existences. On one hand, harness their passion and it’s like bottling lightening. On the other, a more sobering story…
Health for All
Stories matter. They bind people together, create a sense of connection, and engage our thoughts, emotions, and imagination all at once. They show us other people’s perspectives and let us…
Doctored Truths urges pharma to lead the fight against health misinformation
“Doctored Truths” exposes the escalating crisis of health misinformation and disinformation, which has been ranked the world’s top short-term risk to the world, for the second year in a row….
Havas Lynx Welcomes New Leadership Hires
Havas Lynx announces the appointment of Ayesha Walawalkar as Chief Strategy Officer, and Talin Apkarian as Havas Lynx Hudson Managing Director.
Havas to Open New Manchester Village at Circle Square
The global communications group will unite six agencies under one roof in a purpose-built, hybrid workspace at the heart of Manchester’s innovation district
Havas Lynx launches proprietary data product to drive meaningful change across pharma
Leading global healthcare communications agency, Havas Lynx , has launched its proprietary data platform, Point.1, to help pharmaceutical companies to gain a deeper understanding of healthcare professionals (HCPs) to drive…